

Online Resource 1

Manuscript: Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once Daily Efavirenz 400 mg and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Journal: Clinical Pharmacokinetics

Authors: Laura Dickinson, Janaki Amin, Laura Else, Marta Boffito, Deirdre Egan, Andrew Owen, Saye Khoo, David Back, Catherine Orrell, Amanda Clarke, Marcelo Losso, Praphan Phanuphak, Dianne Carey, David A Cooper, Sean Emery, Rebekah Puls, on behalf of the ENCORE1 study group

Corresponding Author Details: Laura Dickinson, Department of Molecular & Clinical Pharmacology, University of Liverpool. laurad@liv.ac.uk

Online Resource 1 Geometric mean (90% CI) of mean individual predicted PK parameters for 400 mg and 600 mg efavirenz. PK parameters estimated using population PK modelling and differences in parameters were assessed by geometric mean ratios (GMR) and 90% CI (n=605).

Parameter	400 mg EFV	600 mg EFV	GMR (90% CI)*
AUC ₀₋₂₄ (mg.h/ L)	49.2 (47.0-51.5)	67.2 (63.8-70.9)	0.73 (0.68-0.78)
C _{max} (mg/L)	2.52 (2.42-2.62)	3.66 (3.51-3.81)	0.69 (0.65-0.73)
C ₂₄ (mg/L)	1.40 (1.32-1.49)	1.82 (1.68-1.97)	0.77 (0.70-0.85)
C ₁₂ (mg/L)	2.10 (2.01-2.20)	2.85 (2.70-3.0)	0.74 (0.69-0.79)

* efavirenz 400mg/efavirenz 600mg

PK: pharmacokinetic; EFV: efavirenz; CI: confidence interval; AUC₀₋₂₄: area under the concentration-time curve over 24 hour interval; C_{max}: maximum concentration; C₂₄: trough concentration, 24 hours post-dose; C₁₂: concentration 12 hours post-dose representing the mid-dose interval

Table also presented in Dickinson L, Amin J, Else L, et al., on behalf of the ENCORE1 Study Group. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther. 2015. doi: 10.1002/cpt.156. **Open Access**, available at: <http://onlinelibrary.wiley.com/doi/10.1002/cpt.156/abstract>